-
-
A pragmatic guide for management of adverse events associated with lorlatinib Lung Cancer (IF 5.3) Pub Date : 2024-03-15 Geoffrey Liu, Julien Mazieres, Jan Stratmann, Sai-Hong Ignatius Ou, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J. Solomon, Todd M. Bauer
Lorlatinib is a brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of anaplastic lymphoma kinase ()-positive metastatic non-small cell lung cancer (NSCLC). In clinical trials, lorlatinib has shown durable efficacy and a manageable safety profile in treatment-naive patients and in those who have experienced progression while receiving first- and/or second-generation
-
Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine Lung Cancer (IF 5.3) Pub Date : 2024-03-14 Josephine A. Taverna, Chia-Nung Hung, Madison Williams, Ryan Williams, Meizhen Chen, Samaneh Kamali, Vaishnavi Sambandam, Cheryl Hsiang-Ling Chiu, Pawel A. Osmulski, Maria E. Gaczynska, Daniel T. DeArmond, Christine Gaspard, Maria Mancini, Meena Kusi, Abhishek N. Pandya, Lina Song, Lingtao Jin, Paolo Schiavini, Chun-Liang Chen
Lung cancer is the leading cause of global cancer-related mortality resulting in ∼ 1.8 million deaths annually. Systemic, molecular targeted, and immune therapies have provided significant improvements of survival outcomes for patients. However, drug resistance usually arises and there is an urgent need for novel therapy screening and personalized medicine. 3D patient-derived organoid (PDO) models
-
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis Lung Cancer (IF 5.3) Pub Date : 2024-03-13 Hyun Ae Jung, Boram Park, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Advanced non-small cell lung cancer patients harboring EGFR mutation or ALK fusion have achieved significant survival benefit with targeted agents. In contrast, EGFR-wild type and ALK negative lung adenocarcinoma still have poor survival outcome. This study assessed the impact of participating in clinical trials on clinical outcomes in patients with EGFR-wild-type and ALK-negative lung adenocarcinoma
-
Comment on: Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas Lung Cancer (IF 5.3) Pub Date : 2024-03-12 Tianfei Yu, Xue Zhou, Ming Li
-
The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer Lung Cancer (IF 5.3) Pub Date : 2024-03-11 Neil D. Wallace, Marliese Alexander, Jing Xie, David Ball, Fiona Hegi-Johnson, Nikki Plumridge, Shankar Siva, Mark Shaw, Susan Harden, Tom John, Ben Solomon, Ann Officer, Michael MacManus
Smoking is a risk factor for the development of lung cancer and reduces life expectancy within the general population. Retrospective studies suggest that non-smokers have better outcomes after treatment for lung cancer. We used a prospective database to investigate relationships between pre-treatment smoking status and survival for a cohort of patients with stage III non-small-cell lung cancer (NSCLC)
-
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study Lung Cancer (IF 5.3) Pub Date : 2024-03-07 Dong-Wan Kim, Byoung Chul Cho, Krishna Pachipala, Sang-We Kim, Chih-Liang Wang, Gee-Chen Chang, Myung-Ju Ahn, Rosa Alvarez, Chao-Hua Chiu, José Trigo, Anna Estival, Sana D. Karam, Cathy O'Brien, Hema Gowda, Haiyi Jiang, Julie E. Bauman
For patients with unresectable, stage III non-small-cell lung cancer (NSCLC), current standard of care is concurrent chemoradiotherapy (cCRT) followed by consolidation durvalumab. However, earlier initiation of durvalumab simultaneously with cCRT may increase antitumor activity relative to initiation after cCRT. The phase 1 CLOVER study (NCT03509012) evaluated durvalumab combined with cCRT in patients
-
Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017 Lung Cancer (IF 5.3) Pub Date : 2024-03-07 R.A.M. Damhuis, C. Dickhoff, I. Bahce, S. Senan
In stage III non-small cell lung cancer (NSCLC), curative treatment approaches used to include neoadjuvant therapy followed by surgery, and definitive chemoradiotherapy followed by consolidation durvalumab (CRT-ICI). Surgical strategies included either neoadjuvant chemotherapy (CTx-surg) or chemoradiotherapy (CRT-surg). We studied the outcomes of these three radical intent strategies in the Netherlands
-
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial Lung Cancer (IF 5.3) Pub Date : 2024-03-04 J. Connor Wells, Monica M. Mullin, Cheryl Ho, Barbara Melosky, Janessa Laskin, Ying Wang, Sophie Sun
Osimertinib is largely used as first-line therapy for metastatic epithelial growth factor receptor (EGFR) mutant lung cancers based on the FLAURA clinical trial. Real-world patient outcomes often differ from clinical trial outcomes. This study evaluated the efficacy of first-line osimertinib in patients treated in British Columbia (BC), Canada. Furthermore, we compared the outcomes of patients who
-
Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment Lung Cancer (IF 5.3) Pub Date : 2024-03-02 Lan-Lan Pang, Wei-Tao Zhuang, Yi-Hua Huang, Jun Liao, Meng-Zhen Li, Yi Lv, Li Zhang, Wen-Feng Fang
The literature on EGFR-mutant patients diagnosed with lung cancer is limited, and there is currently no consensus concerning the most effective treatment protocols. This study aimed to investigate the genomic characteristics of EGFR-mutant non-small cell lung cancer (NSCLC) and provide insights into its clinical response and resistance mechanism to third-generation EGFR-TKIs. Next-generation sequencing
-
Association of patient and health care organization factors with incidental nodule guidelines adherence: A multi-system observational study Lung Cancer (IF 5.3) Pub Date : 2024-02-29 Christopher G. Slatore, Elizabeth R. Hooker, Sarah Shull, Sara E. Golden, Anne C. Melzer
Health care organizations are increasingly developing systems to ensure patients with pulmonary nodules receive guideline-adherent care. Our goal was to determine patient and organization factors that are associated with radiologist adherence as well as clinician and patient concordance to 2005 Fleischner Society guidelines for incidental pulmonary nodule follow-up. Trained researchers abstracted data
-
The Danish lung cancer registry: A nationwide validation study Lung Cancer (IF 5.3) Pub Date : 2024-02-29 Anja Gouliaev, Fatima Ali, Erik Jakobsen, Susanne O. Dalton, Ole Hilberg, Torben R. Rasmussen, Niels L. Christensen
This study evaluates the validity of the information in the Danish Lung Cancer Registry (DLCR). Since 2000, the DLCR has been a tool for monitoring interventions and outcome of all Danish lung cancer patients with the intent to streamline and improve treatment and survival. The DLCR receives information from the Danish Patient Registries in addition to clinical information from the treating physicians
-
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry Lung Cancer (IF 5.3) Pub Date : 2024-02-29 Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Enric Carcereny, Alexandra Cantero, Virginia Calvo, Rafael López Castro, Reyes Bernabé, Joaquim Bosch-Barrera, Bartomeu Massutí, Rosario García Campelo, Alfredo Sánchez-Hernández, Ana Laura Ortega, Maria Guirado, Edel del Barco, Carlos Camps, Joaquin Casal-Rubio, Manuel Dómine, Mª Angeles Sala, Airam Padilla, Jose Luís González Larriba, Francisco
Cancer is a disease of old age; however, most studies usually included minority of patients fit elderly. The purpose is to investigate the clinical characteristics and genetic information of patients with thoracic tumors who are 80 years old or older compared to those under 80 years old. The Thoracic Tumor Registry (TTR) is a Spanish observational, prospective cohort study that included patients diagnosed
-
Lung cancer detection in perioperative patients' exhaled breath with nanomechanical sensor array Lung Cancer (IF 5.3) Pub Date : 2024-02-25 Yusuke Saeki, Naoki Maki, Takahiro Nemoto, Katsushige Inada, Kosuke Minami, Ryo Tamura, Gaku Imamura, Yukiko Cho-Isoda, Shinsuke Kitazawa, Hiroshi Kojima, Genki Yoshikawa, Yukio Sato
[Display omitted]
-
Association between surgical quality and long-term survival in lung cancer Lung Cancer (IF 5.3) Pub Date : 2024-02-25 James D. Lee, Richard Zheng, Olugbenga T. Okusanya, Nathaniel R. Evans, Tyler R. Grenda
There are significant variations in both perioperative and long-term outcomes after lung cancer resection. While perioperative outcomes are often used as comparative measures of quality, they are unreliable, and their association with long-term outcomes remain unclear. In this context, we evaluated whether historical perioperative mortality after lung cancer resection is associated with 5-year survival
-
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels Lung Cancer (IF 5.3) Pub Date : 2024-02-24 Lova Sun, Elizabeth A. Handorf, Yunyun Zhou, Hossein Borghaei, Charu Aggarwal, Jessica Bauman
In patients with advanced NSCLC (aNSCLC), the impact of KRAS mutations (m) and comutations with STK11 and KEAP1 on outcomes across different PD-L1 levels remains incompletely understood. We aimed to investigate the frequency of KRAS mutations and comutations across PD-L1 levels, and the association between these mutations and survival, stratified by PD-L1 expression. We conducted a nationwide cohort
-
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations Lung Cancer (IF 5.3) Pub Date : 2024-02-22 David S. Hong, Federico Cappuzzo, Byoung Chul Cho, Afshin Dowlati, Maen Hussein, Dong-Wan Kim, Ivor Percent, James G. Christensen, Josée Morin, Diane Potvin, Demiana Faltaos, Vanessa Tassell, Hirak Der-Torossian, Richard Chao
Dysregulated signaling by mesenchymal epithelial transition factor (MET) and heightened AXL activation are implicated in the pathogenesis of non-small cell lung cancer (NSCLC). Glesatinib (MGCD265) is an investigational, oral inhibitor of MET and AXL. This open-label, Phase II study investigated glesatinib (free-base suspension [FBS] capsule 1050 mg BID or spray-dried dispersion [SDD] tablet 750 mg
-
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial Lung Cancer (IF 5.3) Pub Date : 2024-02-19 Jean Baptiste Oudart, Simon Garinet, Caroline Leger, Fabrice Barlesi, Julien Mazières, Gaelle Jeannin, Clarisse Audigier-Valette, Denis Morot-Sibilot, Alexandra Langlais, Elodie Amour, Nathalie Mathiot, Gary Birsen, Hélène Blons, Marie Wislez
STK11/LKB1 mutations have been associated with primary resistance to PD-1 axis inhibitors and poor prognosis in advanced KRAS-mutant lung adenocarcinoma. This study aimed to assess the prognostic significance of STK11/LKB1 alterations in localized non-squamous non-small cell lung carcinoma (non-sq NSCLC). Surgical samples from patients undergoing complete resection for stage IIa, IIb, or IIIa (N2 excluded)
-
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782 Lung Cancer (IF 5.3) Pub Date : 2024-02-17 Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, Santiago Ponce Aix, Zsuzsanna Szalai, Enriqueta Felip, Maya Gottfried, Mariano Provencio, Andrew Robinson, Andrea Fülöp, Suman Banner Rao, D. Ross Camidge, Giovanna Speranza, Steven M. Townson, Julie Kobie, Mark Ayers, E.J. Dettman, Nathan Hunkapiller, Robert McDaniel, Byoungsok Jung, David Burkhardt, Ruth Mauntz, Tibor Csőszi
First-line pembrolizumab plus chemotherapy has shown clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC) regardless of tissue tumor mutational burden (tTMB) status. Blood tumor mutational burden (bTMB), assessed using plasma-derived circulating tumor DNA (ctDNA), may be a surrogate for tTMB. The KEYNOTE-782 study evaluated the correlation of bTMB with the efficacy of first-line
-
Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and immune checkpoint inhibition: The relevance of fractionation Lung Cancer (IF 5.3) Pub Date : 2024-02-17 Kim Melanie Kraus, Maksym Oreshko, Julia Anne Schnabel, Denise Bernhardt, Stephanie Elisabeth Combs, Jan Caspar Peeken
Post-therapy pneumonitis (PTP) is a relevant side effect of thoracic radiotherapy and immunotherapy with checkpoint inhibitors (ICI). The influence of the combination of both, including dose fractionation schemes on PTP development is still unclear. This study aims to improve the PTP risk estimation after radio(chemo)therapy (R(C)T) for lung cancer with and without ICI by investigation of the impact
-
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition Lung Cancer (IF 5.3) Pub Date : 2024-02-15 Jonas Saal, Tobias Bald, Markus Eckstein, Damian J. Ralser, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper
A large number of patients with non-small cell lung cancer (NSCLC) on immune checkpoint inhibition (ICI) achieve stable disease (SD) as the best overall response, which is associated with heterogeneous outcomes. In this context, complementary biomarkers that improve outcome prediction are needed. We have recently demonstrated that measuring the on-treatment modified Glasgow prognostic score (mGPS)
-
Response to letter: Microwave ablation for Early-Stage Non-Small cell Lung Cancer: Don’t Put the Cart before the stereotactic Horse Lung Cancer (IF 5.3) Pub Date : 2024-02-14 Paul Laeseke, Calvin Ng, Andrada Naghi, George W.J. Wright, Balaji Laxmanan, Sudip K. Ghosh, Tony B. Amos, Iftekhar Kalsekar, Michael Pritchett
-
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy Lung Cancer (IF 5.3) Pub Date : 2024-02-09 Shasha Wang, Xuezhi Hao, Liyuan Dai, Ning Lou, Guangyu Fan, Ruyun Gao, Mengwei Yang, Puyuan Xing, Yutao Liu, Lin Wang, Zhishang Zhang, Jiarui Yao, Le Tang, Yuankai Shi, Xiaohong Han
Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) has demonstrated remarkable therapeutic effects in -positive non-small cell lung cancer (NSCLC) patients. Identifying prognostic biomarkers can enhance the clinical efficacy of relapsed or refractory patients. We profiled 737 plasma proteins from 159 pre-treatment and on-treatment plasma samples of 63 -positive NSCLC patients using data-independent
-
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma Lung Cancer (IF 5.3) Pub Date : 2024-02-09 Kyoichi Kaira, Hisao Imai, Hiroshi Kagamu
-
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer Lung Cancer (IF 5.3) Pub Date : 2024-02-08 Maria Saigí, Jose L. Mate, Enric Carcereny, Anna Martínez-Cardús, Anna Esteve, Felipe Andreo, Carmen Centeno, Marc Cucurull, Ricard Mesia, Eva Pros, Montse Sanchez-Cespedes
Immune checkpoint inhibitors (ICIs) have provided a breakthrough in the treatment of non-small cell lung cancer (NSCLC) patients, but only some patients benefit substantively. Identifying definitive predictive biomarkers could overcome this limitation. We selected 146 metastatic NSCLC patients treated with anti-PD-(L)1. Immunohistochemistry of HLA-I, PD-L1 and CD73 was performed in 122 tumor biopsies
-
Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer Lung Cancer (IF 5.3) Pub Date : 2024-02-03 Kei Kunimasa, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Akito Miyazaki, Yoshiki Kojitani, Keiichiro Honma, Kazumi Nishino
The Lung Cancer Compact Panel (compact panel) is a gene panel that can detect driver alterations with high sensitivity in liquid samples, including tumor cells. This study examined the ability of a compact panel to detect genetic mutations in liquid specimens used in clinical practice. Three cohorts, bronchoscopic biopsy forceps washing (washing cohort), pleural effusion (pleural cohort), and spinal
-
Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients Lung Cancer (IF 5.3) Pub Date : 2024-01-29 Linus D. Kloker, Mirjana Sidiras, Tim Flaadt, Ines B. Brecht, Christoph K.W. Deinzer, Thorben Groß, Katrin Benzler, Lars Zender, Ulrich M. Lauer
NUT carcinomas (NC) are very rare and highly aggressive tumors, molecularly defined by an aberrant gene fusion involving the NUTM1 gene. NCs preferentially arise intrathoracically or in the head and neck region, having a highly adverse prognosis with almost no long-term survivors. Here, we report on a cohort of 35 adult NC patients who were evaluated at University Hospital Tuebingen in an eight year
-
Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer Lung Cancer (IF 5.3) Pub Date : 2024-01-28 Yun Wang, Chen Hu, Hongwei Yu, Jie Hu, Zhiwei Zhou, Ning Fu, Xiang Huang, Wenchao Wang, Jing Liu
Non-small cell lung cancers (NSCLC) account for 85 % of total lung cancers. Mutation in EGFR drives the progress of NSCLSs with high mortality rate. Besides the common mutations in EGFR, which together comprise of 85 % of all EGFR mutations and respond to the targeted therapy of EGFR tyrosine kinase inhibitors (TKIs), many other low-frequency mutations of EGFR are existed in patients. The oncogenic
-
Incorporation of the lepidic component as an additional pathological T descriptor for non-small cell lung cancer: Data from 3335 cases of lung adenocarcinoma Lung Cancer (IF 5.3) Pub Date : 2024-01-26 Shenghao Huang, Mengmeng Zhao, Shenghui Li, Tao Chen, Yifan Zhong, Jiajun Deng, Long Xu, Junqi Wu, Xiaofeng Xie, Chunyan Wu, Likun Hou, Yunlang She, Hui Zheng, Chang Chen
Objectives The Lepidic Component (LP) identifies a subgroup with an excellent prognosis for lung adenocarcinoma (LUAD). Our research aimed to propose an improved pathological T (pT) stage for LUAD based on LP. Materials and methods Totally, 3335 surgical patients with pathological stage I LUAD were incorporated. Factors affecting survival were investigated by analyzing recurrence-free survival (RFS)
-
-
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy Lung Cancer (IF 5.3) Pub Date : 2024-01-24 Yicong Chen, Huijiao Chen, Ruixuan Yu, Xiaoxiao Zeng, Dong Tian, Qiang Pu, Yongmei Liu
Pulmonary blastomas (PB) are an extremely rare type of lung cancer. Currently, no standard treatment exists for PB. Immunotherapy with checkpoint inhibitors and anti-angiogenesis treatments has been an effective method for lung cancer; however, studies on PB treatment are lacking. Herein, we present a case report of successful conversion therapy with immunotherapy and targeted therapy for PB. After
-
Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab Lung Cancer (IF 5.3) Pub Date : 2024-01-29 Mark Stares, Emma Doyle, Sally Chapple, George Raynes, James MacDonald, Colin Barrie, Barry Laird, Melanie MacKean, Iain Philips
Background Most patients with advanced non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab monotherapy will experience progressive disease (PD). Only a minority will go on to receive subsequent systemic anticancer therapy for which outcomes are guarded. We investigated the prognostic significance of biomarkers of systemic inflammation following failure of first-line pembrolizumab
-
Resolving asbestos and ultrafine particulate definitions with carcinogenicity Lung Cancer (IF 5.3) Pub Date : 2024-01-26 Sean M. Fitzgerald
As asbestos fibers and other fine particles have been studied extensively to correlate physical and chemical properties with their potential for negative human health impact on inhalation, there remains no concise definitions for the individual particle types nor collective considerations of combined variabilities. Extensive studies relating negative health to asbestos morphology, chemistry, surface
-
Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals Lung Cancer (IF 5.3) Pub Date : 2024-01-22 Sylvia A.A.M. Genet, Esther Visser, Maggy Youssef-El Soud, Huub N.A. Belderbos, Gerben Stege, Marleen E.A. de Saegher, Susan C. van 't Westeinde, Luc Brunsveld, Maarten A.C. Broeren, Daan van de Kerkhof, Federica Eduati, Ben E.E.M. van den Borne, Volkher Scharnhorst
Objectives Timely diagnosis of lung cancer (LC) is crucial to achieve optimal patient care and outcome. Moreover, the number of procedures required to obtain a definitive diagnosis can have a large influence on the life expectancy of a patient. Here, adherence with existing Dutch guidelines for timeliness and type and number of invasive and imaging procedures was assessed. Materials and methods 1096
-
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis Lung Cancer (IF 5.3) Pub Date : 2024-01-20 Haicheng Wu, Qian Zhang, Wanchen zhai, Yunfei Chen, Yehao Yang, Mingning Xie, Zhiyu Huang, Yanjun Xu, Hui Li, Lei Gong, Sizhe Yu, Yun Fan, Kaiyan Chen
Background Leptomeningeal metastasis (LM) is associated with an extremely poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The third-generation EGFR-tyrosine kinase inhibitors (TKIs), currently the preferred drug of choice, have significantly improved treatment outcomes in these patients. However, the optimal dose of third-generation
-
International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG study Lung Cancer (IF 5.3) Pub Date : 2024-01-24 Thierry J. Molina, Anja C. Roden, Malgorzata Szolkowska, Shigeki Shimizu, Andre L. Moreira, Lara Chalabreysse, Benjamin Besse, Vincent de Montpréville, Edith M. Marom, Frank Detterbeck, Nicolas Girard, Andrew G. Nicholson, Alexander Marx
Introduction Pathologists are staging thymic epithelial tumors (TET) according to the 8th UICC/AJCC TNM system. Within the French RYTHMIC network, dedicated to TET, agreement on pathologic tumor stage (pT) among the pathology panelists was difficult. The aim of our study was to determine the interobserver reproducibility of pT at an international level, to explore the source of discrepancies and potential
-
A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC) Lung Cancer (IF 5.3) Pub Date : 2024-01-17 N. van Zandwijk, Arthur L. Frank
Abstract not available
-
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced Non-Small cell lung cancer following Platinum-Based doublet chemotherapy and immunotherapy (CANOPY-2): A Multicenter, Randomized, Double-Blind, phase 3 trial Lung Cancer (IF 5.3) Pub Date : 2024-01-16 Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Manuel Cobo, José Luis González Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Bharani Dharan, Martin Reck
Objectives Canakinumab, an interleukin-1 beta inhibitor, previously showed reduced lung cancer incidence and mortality (CANTOS). Here, we compare the efficacy/safety of canakinumab versus placebo in patients with advanced non-small cell lung cancer (NSCLC), who had progressed after platinum-based doublet chemotherapy (PDC) and immunotherapy. Materials and methods CANOPY-2, a randomized, double-blind
-
Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis Lung Cancer (IF 5.3) Pub Date : 2024-01-14 Osamu Noritake, Shota Nakamura, Fumie Kinoshita, Keiju Aokage, Tetsuhiko Asao, Yosuke Matsuura, Toyofumi Fengshi Chen-Yoshikawa
Introduction No evidence exists for postoperative adjuvant therapy in elderly or renal dysfunction patients with non-small-cell lung cancer (NSCLC) who are unfit to receive cisplatin (CDDP). Herein, we evaluated the efficacy of postoperative adjuvant therapy for CDDP-unfit patients. Materials and methods We defined CDDP-unfit patients as those aged ≥75 years or with renal dysfunction based on criteria
-
Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer Lung Cancer (IF 5.3) Pub Date : 2024-01-13 Chi-Lu Chiang, Hsu-Ching Huang, Yung-Hung Luo, Chia-I Shen, Heng-Sheng Chao, Yen-Han Tseng, Teh-Ying Chou, David S. Schrump, Yi-Chen Yeh, Yuh-Min Chen
Objectives Molecular subtyping of small cell lung cancer (SCLC) tumors based on the expression of four transcription factors (ASCL1, NEUROD1, POU2F3, and YAP1) using immunohistochemical (IHC) staining has recently emerged as a proposed approach. This study was aimed to examine this subtyping method in Asian patients with SCLC and investigate its correlation with treatment efficacy. Materials and methods
-
Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy Lung Cancer (IF 5.3) Pub Date : 2024-01-13 Ping Zhou, Yiyun Fu, Yuan Tang, Lili Jiang, Weiya Wang
Background Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a recently recognized distinct clinicopathological entity according to the fifth edition of the 2021 World Health Organization Classification (WHO) for thoracic tumors. Thoracic SMARCA4-UTs are diagnostically challenging to diagnose, especially on small biopsies. Methods We identified 35 thoracic SMARCA4-UTs from the Department
-
-
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions Lung Cancer (IF 5.3) Pub Date : 2024-01-05 Stephen V. Liu, Claas Frohn, Lori Minasi, Kristie Fernamberg, Andrew J. Klink, Ajeet Gajra, Kristin M. Zimmerman Savill, Sushma Jonna
Objectives Neuregulin-1 (NRG1) fusions may drive oncogenesis via constitutive activation of ErbB signaling. Hence, NRG1 fusion-driven tumors may be susceptible to ErbB-targeted therapy. Afatinib (irreversible pan-ErbB inhibitor) has demonstrated activity in individual patients with NRG1 fusion-positive solid tumors. This study collected real-world data on demographics, clinical characteristics, and
-
Prognostic value of predominant subtype in pathological stage II–III lung adenocarcinoma with epidermal growth factor receptor mutation Lung Cancer (IF 5.3) Pub Date : 2023-12-30 Shingo Kitagawa, Yoshitaka Zenke, Tetsuro Taki, Keiju Aokage, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Naoya Sakamoto, Shingo Sakashita, Motohiro Kojima, Masahiro Tsuboi, Koichi Goto, Genichiro Ishii
Objectives This study extracted clinicopathological features associated with recurrence and evaluated the tumor microenvironment in consecutive cases with resected pathological stage II–III epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (EGFR-mt). Methods Between January 2008 and November 2018, we retrospectively reviewed 387 consecutive patients with pathological stage II–III lung
-
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis Lung Cancer (IF 5.3) Pub Date : 2024-01-03 Shen Zhao, Yuxiang Ma, Lianke Liu, Jian Fang, Haiqing Ma, Guosheng Feng, Bo Xie, Shan Zeng, Jianhua Chang, Jun Ren, Yingjun Zhang, Ning Xi, Yulei Zhuang, Yingzhi Jiang, Qi Zhang, Ning Kang, Li Zhang, Hongyun Zhao
Background MET and AXL dysregulations are implicated in acquired resistance to EGFR-TKIs in NSCLC. But consensus on the optimal definition for MET/AXL dysregulations in EGFR-mutant NSCLC is lacking. Here, we investigated the efficacy and tolerability of ningetinib (a MET/AXL inhibitor) plus gefitinib in EGFR-mutant NSCLC, and evaluated the clinical relevance of MET/AXL dysregulations by different definitions
-
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma Lung Cancer (IF 5.3) Pub Date : 2023-12-29 Laura Burns, Hanna Tukachinsky, Kira Raskina, Richard S.P. Huang, Alexa B. Schrock, Jacob Sands, Matthew H. Kulke, Geoffrey R. Oxnard, Umit Tapan
Background Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is an uncommon subtype of lung cancer believed to represent a spectrum of tumors sharing characteristics of both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Other groups have proposed genomic LCNEC subtypes, including small cell-like, non-small cell-like, and carcinoid-like subtypes. The primary goal of this
-
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES) Lung Cancer (IF 5.3) Pub Date : 2023-12-31 Ying Cheng, Lin Wu, Dingzhi Huang, QiMing Wang, Yun Fan, XiQin Zhang, HuiJie Fan, WenXiu Yao, BaoGang Liu, GuoHua Yu, YueYin Pan, Fei Xu, ZhiYong He, XiaoRong Dong, Rui Ma, XuHong Min, XiaoSong Ge, Hualin Chen, Qun Liu, YanPing Hu, Li Zhou
Introduction Trilaciclib is a transient cyclin-dependent kinase 4/6 inhibitor that decreases the incidence of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer (ES-SCLC). TRACES study was designed to assess the safety, efficacy and pharmacokinetics (PK) of trilaciclib before chemotherapy in Chinese patients with ES-SCLC. Methods The study included an open-label safety
-
Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] Lung Cancer (IF 5.3) Pub Date : 2023-12-30 Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, Taiichiro Otsuki, Yuki Sato, Uchida Junji, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke Tsumura, Takuro Sakagami
Abstract not available
-
SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters Lung Cancer (IF 5.3) Pub Date : 2023-12-27 Yao-Hua Zhang, Xu-Sheng Liu, Yan Gao, Ling-Ling Yuan, Zhong-Min Huang, Yu Zhang, Zi-Yue Liu, Yi Yang, Xiao-Yu Liu, Chang-Bin Ke, Zhi-Jun Pei
Background Sideroflexin 1 (SFXN1) has been discovered as a novel tumor marker for lung adenocarcinoma, but data on its importance in the development of lung adenocarcinoma is still limited. This study evaluated the correlation between SFXN1 and parameters related to 18F-flurodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), and further explored the role of SFXN1 in the
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases Lung Cancer (IF 5.3) Pub Date : 2023-12-27 Solange Peters, José Trigo, Benjamin Besse, Victor Moreno, Alejandro Navarro, Maria Eugenia Olmedo, Luis Paz-Ares, Christian Grohé, José Antonio Lopez-Vilariño, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Antonio Nieto, Ali Zeaiter, Vivek Subbiah
Objectives This report focuses on lurbinectedin activity and safety in a subgroup of small cell lung cancer (SCLC) patients from a Basket phase 2 study (Trigo et al. Lancet Oncology 2020;21:645–654) with chemotherapy-free interval (CTFI) ≥ 30 days. This pre-planned analysis was requested for obtaining regulatory approval of lurbinectedin in Switzerland. Materials and methods Patients with extensive-stage
-
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer Lung Cancer (IF 5.3) Pub Date : 2023-12-24 Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, Claude Capron, Florence Parent, Andrei Seferian, Catherine Guettier, Jean-François Emile, Etienne Giroux Leprieur
The identification of biomarkers related to treatment in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) represents a significant challenge. The aim of this study was to determine the predictive value of macrophage-related markers assessed in plasma and tissue samples of patients with NSCLC undergoing ICI treatment. This bicentric study included a prospective
-
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT) Lung Cancer (IF 5.3) Pub Date : 2023-12-19 Cesare Gridelli, Solange Peters, Tony Mok, Marina Garassino, Luis Paz-Ares, Ilaria Attili, Filippo de Marinis
Background The combination of platinum-based chemotherapy with immune-checkpoint inhibitors (ICIs) is a standard of care option in the front-line treatment of advanced non-small cell lung cancer (NSCLC). Positive efficacy and safety results have been demonstrated with different chemo-ICI combinations in the corresponding clinical trials, however no randomized prospective comparison is available and
-
The Effect of Social Vulnerability on Initial Stage and Treatment for Non-Small Cell Lung Cancer Lung Cancer (IF 5.3) Pub Date : 2023-12-23 Christina M. Stuart, Adam R. Dyas, Michael R. Bronsert, Catherine G. Velopulos, Simran K. Randhawa, Elizabeth A. David, John D. Mitchell, Robert A. Meguid
Objective The Social Vulnerability Index (SVI) is a composite metric for social determinants of health. The objective of this study was to determine if SVI influences stage at presentation for non-small cell lung cancer (NSCLC) patients and subsequent therapies. Materials and methods NSCLC patients from our local contribution to the National Cancer Database (2011–2021) were grouped into low SVI (<75 %ile)
-
WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors Lung Cancer (IF 5.3) Pub Date : 2023-12-16 Jian Gao, Yongqiang Ao, Shuai Wang, Zongwei Chen, Yi Zhang, Jianyong Ding, Jiahao Jiang
-
ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report Lung Cancer (IF 5.3) Pub Date : 2023-12-15 Lin Gao, Xinghao Ai, Shun Lu
Introduction Chromosomal rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners occur in non-small cell lung cancers (NSCLCs) and other solid tumors. Novel NTRK rearrangement-related tumors are still being discovered. Methods Herin, we describe a male patient with a mass in the left upper lobe that was biopsied by bronchoscopy. This case
-
Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma Lung Cancer (IF 5.3) Pub Date : 2023-12-14 D.W. Dumoulin, L.H. Douma, M.M. Hofman, V. van der Noort, R. Cornelissen, C.J. de Gooijer, J.A. Burgers, J.G.J.V. Aerts
Objectives Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab improved the survival, however, 30.3% of the patients suffered from grade 3–4 treatment related adverse events (TRAE’s) and TRAE’s led to discontinuation in 23.0% of all patients. Here, we present the first real-world data of nivolumab
-
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) Lung Cancer (IF 5.3) Pub Date : 2023-12-12 A. Cavazzoni, G. Digiacomo, F. Volta, R. Alfieri, E. Giovannetti, L. Gnetti, L. Bellini, M. Galetti, C. Fumarola, G. Xu, M. Bonelli, S. La Monica, M. Verzè, A. Leonetti, K. Eltayeb, S. D'Agnelli, L. Moron Dalla Tor, R. Minari, P.G. Petronini, M. Tiseo
Background Monoclonal antibodies (ICI) targeting the immune checkpoint PD-1/PD-L1 alone or in combination with chemotherapy have demonstrated relevant benefits and established new standards of care in first-line treatment for advanced non-oncogene addicted non-small cell lung cancer (NSCLC). However, a relevant percentage of NSCLC patients, even with high PD-L1 expression, did not respond to ICI, highlighting
-
Micropapillary and solid components as high-grade patterns in IASLC grading system of lung adenocarcinoma: Clinical implications and management Lung Cancer (IF 5.3) Pub Date : 2023-12-16 Masashi Mikubo, Satoru Tamagawa, Yasuto Kondo, Shoko Hayashi, Dai Sonoda, Masahito Naito, Kazu Shiomi, Masaaki Ichinoe, Yukitoshi Satoh
Objectives The grading system proposed by the International Association for the Study of Lung Cancer is based on a combination of predominant histologic subtypes and the proportion of high-grade components with a cutoff of 20%. We aimed to examine the clinical implications of the grading system beyond the discrimination of patient prognosis, while assessing the biological differences among high-grade
-
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program Lung Cancer (IF 5.3) Pub Date : 2023-12-15 Francesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, Giulia Pasello, Gabriele Minuti, Alessandra Bulotta, Domenico Galetta, Giacomo Pelizzari, Claudio Sini, Emilio Bria, Elisa Roca, Sara Pilotto, Carlo Genova, Giulio Metro, Fabrizio Citarella, Rita Chiari, Diego Cortinovis, Angelo Delmonte, Alessandro Russo, Marcello Tiseo, Silvia Novello
Background Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality of life over docetaxel in patients with KRASp.G12C–mutated advanced non–small-cell lung cancer (NSCLC) within the CodeBreak-200 study. Here we report real-world efficacy and tolerability data from NSCLC patients who received sotorasib within the Italian expanded access program (EAP). Methods
-
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer Lung Cancer (IF 5.3) Pub Date : 2023-12-15 Byoung Chul Cho, Chao-Hua Chiu, Erminia Massarelli, Gary L. Buchschacher, Koichi Goto, Tobias R. Overbeck, Herbert H.F. Loong, Cheng E. Chee, Pilar Garrido, Xiaorong Dong, Yun Fan, Shun Lu, Sven Schwemmers, Walter Bordogna, Harald Zeuner, Stuart Osborne, Thomas John
Objectives NTRK fusions result in constitutively active oncogenic TRK proteins responsible for ∼ 0.2 % of non-small cell lung cancer (NSCLC) cases. Approximately 40 % of patients with advanced NSCLC develop CNS metastases; therefore, treatments with intracranial (IC) efficacy are needed. In an integrated analysis of three phase I/II studies (ALKA-372–001: EudraCT 2012–000148–88; STARTRK-1: NCT02097810;